Evidence map›Paper›PMID 28972081›Full record

ArticleMolecular & cellular proteomics : MCP2017

Unique Interactome Network Signatures for Peroxisome Proliferator-activated Receptor Gamma (PPARγ) Modulation by Functional Selective Ligands.

Vinh Q Lam, Jie Zheng, Patrick R Griffin

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases.International journal of molecular sciences · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Vinh Q Lam‡From the Department of Molecular Medicine, The Scripps Research Institute, Scripps, Florida, Jupiter, Florida 33458.
Jie Zheng‡From the Department of Molecular Medicine, The Scripps Research Institute, Scripps, Florida, Jupiter, Florida 33458.
Patrick R Griffin‡From the Department of Molecular Medicine, The Scripps Research Institute, Scripps, Florida, Jupiter, Florida 33458 pgriffin@scripps.edu.
Scripps Research Institute · US

Funding

Molecular Characterization of Novel Insulin SensitizersR01DK105825 · NIDDK · SCRIPPS FLORIDA · PI GRIFFIN, PATRICK ROBERT · 2015 to 2019
$2.9M
NIDDK NIH HHS R01 DK105825
6 · The paper itself

Abstract

The nuclear receptor PPARγ regulates adipogenesis and plays a central role in lipid and glucose homeostasis, and is the molecular target of the glitazones (TZDs), therapeutics used to treat insulin resistance and type-2 diabetes (T2D). Although the TZDs, which are PPARγ agonists, demonstrated robust clinical efficacy in T2D, their use has been hampered by an array of untoward side effects. Paradoxically, partial agonists (

Indexed as

3T3 CellsAdipocytesAnimalsBiphenyl CompoundsCell DifferentiationCells, CulturedCytosolHumansIndolesLigandsMicePPAR gammaProtein BindingProtein Interaction MappingProtein Interaction MapsRosiglitazoneBiphenyl CompoundsIndolesLigandsPPAR gammaRosiglitazone(S)-4'-((5-((1-(4-nitrophenyl)ethyl)carbamoyl)-1H-indol-1-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acidSR2595Thiazolidinediones

Identifiers

PMID28972081
PMCPMC5724174
OpenAlexW2774550664

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.